OncWonk – Dr Bier's Oncology Research Reviews – Page 9

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis

November 2, 2025

| ADT - Androgen Deprivation, Cancer - Prostate

Comment: This meta-analysis provides important, ‘Moderate’ certainty evidence that supports a clinical approach that’s simple to implement. The key takeaway is the non-inferiority of intermittent androgen deprivation (IAD) regarding overall survival. While the summary notes minimal difference in overall quality of life, the qualitative data suggesting improvements in physical and sexual functioning is clinically significant. […]

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

November 2, 2025

| No Comments

| Miscellaneous

Comment: This 2017 article’s real contribution here isn’t the narrative review—which, as is too selective to be high-quality—but the new VICTOR-2 subgroup data. While a 35.7% Clinical Benefit Rate in an elderly (median age 69) metastatic TNBC population is certainly interesting, it’s from a tiny, single-arm cohort of 28 patients. This paper highlights metronomic chemotherapy […]

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

November 2, 2025

| No Comments

| Cancer - Breast

Comment: Metronomic chemotherapy (mCHT) is a concept that’s been around, but it’s often overlooked in favor of high-dose regimens. This 2022 review from J. Clin. Med. brilliantly frames the evidence, separating the clear “lights”—like its low-toxicity profile—from the persistent “shadows” we still face, such as the lack of large randomized trials. For our frail or […]

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

November 2, 2025

| No Comments

| Miscellaneous

Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]

Thyroxine promotes lung cancer growth in an orthotopic mouse model

November 1, 2025

| No Comments

| Cancers, Medications - General Pharmaceuticals

Comment: This is an important pre-clinical study, adding another piece to the connection between levothyroxine and cancer. The finding that T4 promotes tumor growth not by direct cell stimulation, but by driving neoangiogenesis via the integrin αvβ3 receptor, is a critical piece of biologic plausibility. Of course, the major caveat is that this is a […]

The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research

November 1, 2025

| No Comments

| Cancers, Immunotherapy & Targeted Therapies, Medications - General Pharmaceuticals

Comment: This is a fascinating review of a complex topic. The key clinical pearl here is the paradoxical finding that treatment-induced hypothyroidism (from TKIs/ICPis) often correlates with a favorable prognosis. It underscores the need to closely monitor thyroid function in these patients—not just as a side effect to be managed, but as a potential prognostic […]

Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

October 29, 2025

| No Comments

| Cancers, Statistics

Comment: Unfortunately, this study confirms a persistent issue. We repeatedly see this major discrepancy between the “known unknowns”—the clinical uncertainties the FDA rightly identifies during expedited approvals—and what actually gets published in high-impact journals and translated into clinical guidelines like the NCCN. The result is that frontline oncologists are often making treatment decisions with an […]

Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials

October 27, 2025

| No Comments

| Cancer - Colon

Comment: This systematic review is, predictably, hampered by significant heterogeneity and an insufficient number of trials, preventing any definitive conclusions. However, an optimistic signal does emerge. The review strongly reinforces the primary value proposition of metronomic chemotherapy: an exceptionally favorable safety profile, with a striking lack of severe hematological toxicity. Furthermore, despite the mixed data, […]

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer

October 26, 2025

| No Comments

| Cancer - Colon

Comment: While this study is flawed by its retrospective design and critical selection bias, we shouldn’t discard the core hypothesis. The authors are right to call the findings preliminary, but the concept of metronomic maintenance therapy remains highly compelling. The fact that such a strong Overall Survival signal (86.8% vs. 68.5%) was detected at all, […]

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

October 26, 2025

| No Comments

| Cancer - Breast

Comment: The MECCA trial, while certainly not practice-changing, provides an important signal for the potential of metronomic chemotherapy. The key takeaway is the therapeutic window. Achieving a 9-month PFS benefit and a positive OS trend with a regimen that produced Grade 3 adverse events in only 15.1% of patients is compelling. This highlights the central […]